← Eichor
Study identifier: NCT05057468 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Second-line Treatment of Primary Autoimmune Hemolytic Anemia

Condition: Primary Autoimmune Hemolytic Anemia  ·  Sponsor: Assiut University

PhasePhase 3
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

the cyclosporine showed efficacy in many immune cytopenic diseases in the light of numerous case reports and retrospective data. This study compares cyclosporin versus rituximab in steroid-refractory anemia.

This description comes directly from the study's public registry record.

Talk to the study team

ghada Abdallah  ·  +201008138002  ·  ghadaelsayed2008@yahoo.com

Always discuss trial participation with your own doctor first.

Locations (2)

Assiut university hospitalAsyut, Asyut Governorate, EgyptActive Not Recruiting
Assiut university hospitalAsyut, Asyut Governorate, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05057468